Inhibikase Therapeutics (IKT) Return on Sales (2020 - 2024)
Inhibikase Therapeutics (IKT) has disclosed Return on Sales for 5 consecutive years, with 20063937.0% as the latest value for Q3 2024.
- On a quarterly basis, Return on Sales fell 2006387707.0% to 20063937.0% in Q3 2024 year-over-year; TTM through Sep 2024 was 20063937.0%, a 2006387522.0% decrease, with the full-year FY2023 number at 77.12%, up 6974.0% from a year prior.
- Return on Sales was 20063937.0% for Q3 2024 at Inhibikase Therapeutics, down from 238.85% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 1.87% in Q1 2021 to a low of 20063937.0% in Q3 2024.
- A 5-year average of 1288008.65% and a median of 68.2% in 2022 define the central range for Return on Sales.
- Peak YoY movement for Return on Sales: surged 252523bps in 2022, then crashed 2000000000bps in 2024.
- Inhibikase Therapeutics' Return on Sales stood at 7.09% in 2020, then crashed by -36487bps to 2593.43% in 2021, then surged by 97bps to 68.2% in 2022, then tumbled by -6457080bps to 4403566.0% in 2023, then crashed by -356bps to 20063937.0% in 2024.
- Per Business Quant, the three most recent readings for IKT's Return on Sales are 20063937.0% (Q3 2024), 238.85% (Q2 2024), and 102.85% (Q1 2024).